As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Oncolytics Biotech, Inc. The largest reported stake is Anson Funds Management LP's, at 7%. One filing is on record since November 14, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Oncolytics Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Anson Funds Management LP · Sole voting: 0 · Shared voting: 7,649,050 · Sole dispositive: 0 · Shared dispositive: 7,649,050 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Anson Management GP LLC · Sole voting: 0 · Shared voting: 7,649,050 · Sole dispositive: 0 · Shared dispositive: 7,649,050 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Tony Moore · Sole voting: 0 · Shared voting: 7,649,050 · Sole dispositive: 0 · Shared dispositive: 7,649,050 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Anson Advisors Inc. · Sole voting: 0 · Shared voting: 7,649,050 · Sole dispositive: 0 · Shared dispositive: 7,649,050 · SCHEDULE 13G/A, 2025-11-14
- · Reporting person: Amin Nathoo · Sole voting: 0 · Shared voting: 7,649,050 · Sole dispositive: 0 · Shared dispositive: 7,649,050 · SCHEDULE 13G/A, 2025-11-14
Oncolytics Biotech, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-14. 1 holder's latest filing reports 5% or more of common stock, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Anson Funds Management LP | 7% | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Oncolytics Biotech, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Oncolytics Biotech, Inc. and the records around it.
Oncolytics Biotech, Inc. elsewhere on the record
- Leadership changes Jun 2026
Companies that share a holder
- Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)
Watch Oncolytics Biotech, Inc.
Get an email when Oncolytics Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Oncolytics Biotech, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Oncolytics Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oncolytics Biotech, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Anson Funds Management LP | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
| Anson Management GP LLC | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
| Tony Moore | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
| Anson Advisors Inc. | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
| Amin Nathoo | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
| Moez Kassam | 0 | 7,649,050 | 0 | 7,649,050 | SCHEDULE 13G/A, 2025-11-14 |
The latest filing names Oncolytics Biotech, Inc., with its principal executive office as 804, 322 - 11 AVENUE SW, CALGARY (SCHEDULE 13G/A, 2025-11-14).
What the percentages are based on
Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 7% of the outstanding shares of Common Stock, which includes shares of Common Stock underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr.Anson Funds Management LP, SCHEDULE 13G/A, 2025-11-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Anson Funds Management LP | 7% | SCHEDULE 13G/A |
Also on the record for Oncolytics Biotech, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 2, 2026 | Leadership change: John McAdory appointed, Chief Operating Officer, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Oncolytics Biotech, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.